The Experts below are selected from a list of 216 Experts worldwide ranked by ideXlab platform

Baruch Yerushalmi - One of the best experts on this subject based on the ideXlab platform.

  • subclinical intestinal inflammation in Chronic Granulomatous Disease patients
    Immunologic Research, 2016
    Co-Authors: Arnon Broides, Orli Sagi, Vered Pinsk, Jacov Levy, Baruch Yerushalmi
    Abstract:

    Chronic Granulomatous Disease is a primary immunodeficiency caused by impaired neutrophil production of reactive oxygen species. Non-infectious colitis is common in Chronic Granulomatous Disease, and high levels of antimicrobial antibodies that are associated with Crohn's Disease are common even without colitis. Fecal calprotectin concentration is a marker for intestinal inflammation. We sought to determine whether subclinical intestinal inflammation occurs in asymptomatic Chronic Granulomatous Disease patients. Asymptomatic Chronic Granulomatous Disease patients without overt gastrointestinal symptoms suggestive of colitis at the time of enrollment were studied for fecal calprotectin concentration, antibodies associated with Crohn's Disease and systemic inflammatory markers. Eight patients were included, aged 54-176 months. In 7/8 (87.5 %) fecal calprotectin concentration was normal (<50) and elevated (137 mg/kg) in only one patient. This patient later developed colitis. In 7/8 (87.5 %) anti-Saccharomyces cerevisiae antibody was positive. C-reactive protein, albumin, complete blood count and p-anti-neutrophil cytoplasmic antibody were normal in all 8 patients. Subclinical colitis is not evident in most asymptomatic Chronic Granulomatous Disease patients; however, in some patients, fecal calprotectin concentration may be elevated, possibly indicating the presence of subclinical colitis and predicting the occurrence of clinically relevant colitis. Serum anti-Saccharomyces cerevisiae antibody concentrations do not seem to correlate with fecal calprotectin concentration in asymptomatic Chronic Granulomatous Disease patients.

  • Subclinical intestinal inflammation in Chronic Granulomatous Disease patients.
    Immunologic research, 2015
    Co-Authors: Arnon Broides, Orli Sagi, Vered Pinsk, Jacov Levy, Baruch Yerushalmi
    Abstract:

    Chronic Granulomatous Disease is a primary immunodeficiency caused by impaired neutrophil production of reactive oxygen species. Non-infectious colitis is common in Chronic Granulomatous Disease, and high levels of antimicrobial antibodies that are associated with Crohn's Disease are common even without colitis. Fecal calprotectin concentration is a marker for intestinal inflammation. We sought to determine whether subclinical intestinal inflammation occurs in asymptomatic Chronic Granulomatous Disease patients. Asymptomatic Chronic Granulomatous Disease patients without overt gastrointestinal symptoms suggestive of colitis at the time of enrollment were studied for fecal calprotectin concentration, antibodies associated with Crohn's Disease and systemic inflammatory markers. Eight patients were included, aged 54-176 months. In 7/8 (87.5 %) fecal calprotectin concentration was normal (

David Mckenna - One of the best experts on this subject based on the ideXlab platform.

  • Chronic Granulomatous Disease carrier with recurrent poor obstetric outcome.
    Obstetrics & Gynecology, 2014
    Co-Authors: Ziad Haidar, Amol Malshe, David Mckenna
    Abstract:

    BACKGROUND Chronic Granulomatous Disease is a primary immunodeficiency disorder characterized by severe recurrent bacterial and fungal infections. Female carriers of the X-linked form of the disorder usually are unaffected and rarely have serious infections. CASE A 22-year-old pregnant patient known to be a carrier of the X-linked form of Chronic Granulomatous Disease had a history of chorioamnionitis during her two previous pregnancies. During her third pregnancy, she presented again with the same diagnosis, which resulted in delivery at 25 weeks of gestation. CONCLUSION Carriers of Chronic Granulomatous Disease should be monitored closely during pregnancy, as if they have the Disease. To decrease the risk of infectious morbidity and mortality, obstetricians should have a low threshold for starting prophylactic antibiotics early during pregnancy, even if the patient is asymptomatic.

  • Chronic Granulomatous Disease carrier with recurrent poor obstetric outcome.
    Obstetrics and gynecology, 2014
    Co-Authors: Ziad A Haidar, Amol Malshe, David Mckenna
    Abstract:

    Chronic Granulomatous Disease is a primary immunodeficiency disorder characterized by severe recurrent bacterial and fungal infections. Female carriers of the X-linked form of the disorder usually are unaffected and rarely have serious infections. A 22-year-old pregnant patient known to be a carrier of the X-linked form of Chronic Granulomatous Disease had a history of chorioamnionitis during her two previous pregnancies. During her third pregnancy, she presented again with the same diagnosis, which resulted in delivery at 25 weeks of gestation. Carriers of Chronic Granulomatous Disease should be monitored closely during pregnancy, as if they have the Disease. To decrease the risk of infectious morbidity and mortality, obstetricians should have a low threshold for starting prophylactic antibiotics early during pregnancy, even if the patient is asymptomatic.

Arnon Broides - One of the best experts on this subject based on the ideXlab platform.

  • subclinical intestinal inflammation in Chronic Granulomatous Disease patients
    Immunologic Research, 2016
    Co-Authors: Arnon Broides, Orli Sagi, Vered Pinsk, Jacov Levy, Baruch Yerushalmi
    Abstract:

    Chronic Granulomatous Disease is a primary immunodeficiency caused by impaired neutrophil production of reactive oxygen species. Non-infectious colitis is common in Chronic Granulomatous Disease, and high levels of antimicrobial antibodies that are associated with Crohn's Disease are common even without colitis. Fecal calprotectin concentration is a marker for intestinal inflammation. We sought to determine whether subclinical intestinal inflammation occurs in asymptomatic Chronic Granulomatous Disease patients. Asymptomatic Chronic Granulomatous Disease patients without overt gastrointestinal symptoms suggestive of colitis at the time of enrollment were studied for fecal calprotectin concentration, antibodies associated with Crohn's Disease and systemic inflammatory markers. Eight patients were included, aged 54-176 months. In 7/8 (87.5 %) fecal calprotectin concentration was normal (<50) and elevated (137 mg/kg) in only one patient. This patient later developed colitis. In 7/8 (87.5 %) anti-Saccharomyces cerevisiae antibody was positive. C-reactive protein, albumin, complete blood count and p-anti-neutrophil cytoplasmic antibody were normal in all 8 patients. Subclinical colitis is not evident in most asymptomatic Chronic Granulomatous Disease patients; however, in some patients, fecal calprotectin concentration may be elevated, possibly indicating the presence of subclinical colitis and predicting the occurrence of clinically relevant colitis. Serum anti-Saccharomyces cerevisiae antibody concentrations do not seem to correlate with fecal calprotectin concentration in asymptomatic Chronic Granulomatous Disease patients.

  • Subclinical intestinal inflammation in Chronic Granulomatous Disease patients.
    Immunologic research, 2015
    Co-Authors: Arnon Broides, Orli Sagi, Vered Pinsk, Jacov Levy, Baruch Yerushalmi
    Abstract:

    Chronic Granulomatous Disease is a primary immunodeficiency caused by impaired neutrophil production of reactive oxygen species. Non-infectious colitis is common in Chronic Granulomatous Disease, and high levels of antimicrobial antibodies that are associated with Crohn's Disease are common even without colitis. Fecal calprotectin concentration is a marker for intestinal inflammation. We sought to determine whether subclinical intestinal inflammation occurs in asymptomatic Chronic Granulomatous Disease patients. Asymptomatic Chronic Granulomatous Disease patients without overt gastrointestinal symptoms suggestive of colitis at the time of enrollment were studied for fecal calprotectin concentration, antibodies associated with Crohn's Disease and systemic inflammatory markers. Eight patients were included, aged 54-176 months. In 7/8 (87.5 %) fecal calprotectin concentration was normal (

Alice Prince - One of the best experts on this subject based on the ideXlab platform.

  • Treatment of intractable gastrointestinal manifestations of Chronic Granulomatous Disease with cyclosporine
    The Journal of pediatrics, 1995
    Co-Authors: Joel R. Rosh, Hope B. Tang, Lloyd Mayer, Gabriel M. Groisman, Sheeja K. Abraham, Alice Prince
    Abstract:

    Abstract Gastrointestinal manifestations of Chronic Granulomatous Disease of childhood include Granulomatous inflammatory bowel Disease. Severe colitis and perirectal Disease developed in a 12-year-old boy with Chronic Granulomatous Disease while he was receiving interferon gamma therapy. The boy had a deficiency of the 22 kd light chain of the cytochrome b heterodimer. After conventional medical therapy proved to be ineffective, a rapid clinical response was obtained to cyclosporine. (J PEDIATR 1995;126:143-5)

Jacov Levy - One of the best experts on this subject based on the ideXlab platform.

  • subclinical intestinal inflammation in Chronic Granulomatous Disease patients
    Immunologic Research, 2016
    Co-Authors: Arnon Broides, Orli Sagi, Vered Pinsk, Jacov Levy, Baruch Yerushalmi
    Abstract:

    Chronic Granulomatous Disease is a primary immunodeficiency caused by impaired neutrophil production of reactive oxygen species. Non-infectious colitis is common in Chronic Granulomatous Disease, and high levels of antimicrobial antibodies that are associated with Crohn's Disease are common even without colitis. Fecal calprotectin concentration is a marker for intestinal inflammation. We sought to determine whether subclinical intestinal inflammation occurs in asymptomatic Chronic Granulomatous Disease patients. Asymptomatic Chronic Granulomatous Disease patients without overt gastrointestinal symptoms suggestive of colitis at the time of enrollment were studied for fecal calprotectin concentration, antibodies associated with Crohn's Disease and systemic inflammatory markers. Eight patients were included, aged 54-176 months. In 7/8 (87.5 %) fecal calprotectin concentration was normal (<50) and elevated (137 mg/kg) in only one patient. This patient later developed colitis. In 7/8 (87.5 %) anti-Saccharomyces cerevisiae antibody was positive. C-reactive protein, albumin, complete blood count and p-anti-neutrophil cytoplasmic antibody were normal in all 8 patients. Subclinical colitis is not evident in most asymptomatic Chronic Granulomatous Disease patients; however, in some patients, fecal calprotectin concentration may be elevated, possibly indicating the presence of subclinical colitis and predicting the occurrence of clinically relevant colitis. Serum anti-Saccharomyces cerevisiae antibody concentrations do not seem to correlate with fecal calprotectin concentration in asymptomatic Chronic Granulomatous Disease patients.

  • Subclinical intestinal inflammation in Chronic Granulomatous Disease patients.
    Immunologic research, 2015
    Co-Authors: Arnon Broides, Orli Sagi, Vered Pinsk, Jacov Levy, Baruch Yerushalmi
    Abstract:

    Chronic Granulomatous Disease is a primary immunodeficiency caused by impaired neutrophil production of reactive oxygen species. Non-infectious colitis is common in Chronic Granulomatous Disease, and high levels of antimicrobial antibodies that are associated with Crohn's Disease are common even without colitis. Fecal calprotectin concentration is a marker for intestinal inflammation. We sought to determine whether subclinical intestinal inflammation occurs in asymptomatic Chronic Granulomatous Disease patients. Asymptomatic Chronic Granulomatous Disease patients without overt gastrointestinal symptoms suggestive of colitis at the time of enrollment were studied for fecal calprotectin concentration, antibodies associated with Crohn's Disease and systemic inflammatory markers. Eight patients were included, aged 54-176 months. In 7/8 (87.5 %) fecal calprotectin concentration was normal (